Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data

Diagnostic tests often fail to lead to changes in patient outcomes

(2014) Konstantinos C. Siontis et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Fracture mortality: associations with epidemiology and osteoporosis treatment

(2014) Sebastian E. Sattui et al.   Nature Reviews Endocrinology

Criteria for monitoring tests were described: validity, responsiveness, detectability of long-term change, and practicality

(2013) Katy J.L. Bell et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

(2012) Richard M Jacques et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The potential value of monitoring bone turnover markers among women on alendronate

(2011) Katy JL Bell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis

(2009) Pierre D Delmas et al.   JOURNAL OF BONE AND MINERAL RESEARCH